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Abstract
Background: Accumulated evidences have shown that vascular risk factors, e.g., hypertension, diabetes mellitus and
hyperlipidemia, may be related to the risk of dementia. This study investigated the association between genetic
polymorphisms of a vascular susceptibility gene, Ninjurin2 (NINJ2), and the risk of dementia, which has not been explored
previously.
Methods: A total of 275 Alzheimer’s disease (AD) patients and 119 vascular dementia (VaD) patients aged 50 or older
were recruited from three teaching hospitals from 2007 to 2010. Healthy controls (n=423) with the same age of cases
were recruited from the health checkup and volunteers worked at the hospital during the same time period. Five
common (frequency .5%) haplotype-tagging single nucleotide polymorphisms (htSNPs) in NINJ2 were genotyped to
test for the association between sequence variants of NINJ2 and dementia risk, and how vascular risk factors modify this
association.
Results: Homozygosity of two NINJ2 SNPs was significantly associated with a decreased risk of AD [rs11833579: adjusted
odds ratio (AOR)=0.43; 95% confidence interval (CI) =0.23–0.80; rs12425791: AOR =0.33, 95% CI =0.12–0.96]. Five
common haplotypes (cumulative frequency =97%) were identified. The global test for the association between NINJ2
haplotypes and AD was significant (p=0.03). Haplotype CAGGA was significantly associated with a decreased risk of AD
(AOR =0.32, 95% CI =0.11–0.94). No associations were observed for VaD.
Conclusion: Inherited polymorphisms of the vascular susceptibility gene NINJ2 were associated with AD risk.
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Introduction
Dementia is a common neurodegenerative disorders in the
elderly. In the United States, dementia ranked the fifth and eighth
leading cause of death in women and men aged 65 years or older
in 2003, respectively [1]. In Taiwan, the aging rate ranks 2
nd in the
world and the prevalence of dementia ranged from 2.5% to 4.4%
in the elderly in 1990s [2,3]. Therefore, dementia is an important
health issue in the aging population.
Hypercholesteremia, diabetes mellitus (DM), hypertension, apo-
lipoprotein E (APOE) genotype, and atherosclerosis are vascular
risk factors involved in chronic inflammation, neurotoxicity and
neurodegeneration, which lead to the subsequent cerebral vascular
disease, vascular dementia (VaD), and Alzheimer’s disease (AD)
previously [4,5,6,7]. Limited vascular susceptibility genes were
identified in a previous genome-wide association studies (GWAS)
for AD risk [8]. A recent GWAS found two single nucleotide
polymorphisms (SNPs), rs11833579 and rs12425791, near NINJ2
were associated with the risk of ischemic stroke [9]. Ischemic
stroke and dementia share common mechanisms in pathophysi-
ology, e.g., cerebral hypoperfusion, neurotoxicity, and inflamma-
tion [10,11]. Therefore, it is possible that NINJ2 plays an
important vascular role in AD pathogenesis.
NINJ2 is a transmembrane protein that mediates cell-to-cell
and cell-to-extracellular matrix interactions during development,
differentiation, and regeneration of the nervous system [12,13,14].
The gene encodes NINJ2 is located on chromosome 12p13. It
is expressed in brain radial glia cell and lymphocytes [13] and is
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outgrowth and has been related to ischemic tolerance [13]. NINJ2
also interacts with several substances, e.g., L1, N-CAM, and J1
adhesion molecules, which may coordinate a cascade of
interactions between leukocyte and endothelial cells and thus
plays an important role on the pathogenesis of inflammatory
disorder [15,16]. These mechanisms have been linked to the
development of dementia [17]. Therefore, this study was aimed to
examine the association between genetic polymorphisms of NINJ2
and the risk of AD and VaD. In addition, effect modification by
vascular risk factors were explored.
Materials and Methods
Study Population
This was a case-control study. A total of 394dementia cases
were recruited from the neurology clinics of three teaching
hospitals in northern Taiwan from November 2007 to July 2010.
Healthy controls (n=443) were recruited from geriatric health
checkup and volunteers of the hospital during the same period of
time. All participants were aged 50 years or older and were
excluded if they had the history of depression, Parkinson’s disease,
hemorrhagic stroke, cerebral infarction, or brain tumor. In
addition, dementia subtypes other than AD and VaD were
excluded. After exclusion of participants without blood samples,
275 AD, 119 VaD patients and 423 controls were included for
data analysis. This study was approved by the Institutional Review
Boards of En Chu Kong Hospital, Cardinal Tien’s Hospital, and
College of Public Health, National Taiwan University. Written
informed consent was obtained from each study participant. The
consent from the legal guardian/next of kin was obtained when
patients had serious cognitive impairment.
A self-reported questionnaire was administered to collect
information on demography, vascular risk factors, lifestyle, and
family history of disease. Blood sample was collect in tubes
containing sodium EDTA from each participant. After centri-
fuged, genomic DNA was extracted from buffy coat by using
QuickGene-Mini80 system (Fujifilm, Tokyo, Japan) and then
stored in a 280uC freezer.
Dementia Evaluation
At each hospital, one neurologist performed clinical examina-
tions to screen potential dementia cases. Mini-Mental State
Examination (MMSE) and Clinical Dementia Rating (CDR) were
used to assess their cognitive function. The diagnosis of dementia
was evaluated by Diagnostic and Statistical Manual of Mental
Disorders (Fourth Edition) [18] criteria. Head images, computed
tomography and magnetic resonance imagings, were taken to
confirm the subtype of dementia. Diagnosis of probable (typical
AD presentation) AD was based on the National Institute of
Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) Alzheimer’s Criteria [19].
Diagnosis of VaD was made according to National Institute of
Neurological Disorders and Stroke-Association Internationale
pour la Recherche et l’Enseignement en Neurosciences (NINDS-
AIREN) criteria [20]. Because of different etiology beween large-
and small-vessel dementia, only VaD patients with small vessel
related stroke (e.g., lacunar infarction and leukoaraiosis) were
recruited. The cognitive function of controls was assessed using
Short Portable Mental Status Questionnaire [21] to exclude
participants with possible dementia and other mental disorders,
e.g., Parkinson’s disease and meningioma.
SNP Selection and Genotyping Assay
Common (frequency .0.05) SNPs in NINJ2 were identified
from Han Chinese in Beijing, China (CHB) genotype data of the
International HapMap Project (http://hapmap.ncbi.nlm.nih.
gov). Haplotype block was defined by Haploview (http://www.
broadinstitute.org/haploview/haploview) using the modified Ga-
briel algorithm [22,23]. Haplotype-tagging SNPs (htSNPs) were
selected from these common SNPs using tagSNP program [24].
SNPs, rs11833579 and rs12425791, associated with stroke risk in a
previous GWAS [9] were also included. APOE genotypes were
determined by the assay developed by Chapman et al. [25]
TaqMan Assay (Applied Biosystems Inc., CA, USA) was used to
determine genotypes of NINJ2 htSNPs. Genotyping success rate
was greater than 95% for all SNPs. Quality control samples were
replicates of 5% study participants and the concordance rate was
100%.
Statistical Analysis
The Hardy-Weinberg equilibrium (HWE) test was performed to
examine possible genotyping error for each SNP among controls.
The expectation-maximization algorithm was applied to estimate
haplotype frequencies. Logistic regression models were used to
estimate adjusted odds ratios (AORs) and 95% confidence
intervals (CIs) for dementia (AD or VaD) in participants carrying
either one or two versus zero copies of the minor allele of each
SNP and each multilocus haplotype. Age, gender, and APOE e4
status were adjusted in the models as potential confounders. The
type I error rate was controlled by false discovery rate (FDR) and
the single multiple-degree-of-freedom test (global test) for the
association between NINJ2 SNPs or haplotypes and dementia risk.
Given a significant global test, haplotype- and SNP-specific tests
can provide some guidance as to which variant(s) contributes to
the significant global test.
Vascular risk factors [e.g., body mass index (BMI), smoking
history, alcohol consumption, DM, hypertension, hyperlipidemia,
cardiovascular disease, APOE e4 status] were known risk factors of
Table 1. Characteristics of the study population.
Variables
AD
N=275
VaD
N=119
Control
N=423
Age (mean6SD) 78.268.0* 78.667.1* 71.467.4
Female (%) 180 (65)* 63 (53) 240 (57)
Education (%)
#6 years
6–12years
.12 years
139 (51)*
95 (35)
41 (15)
72 (59)*
36 (30)
14 (11)
43 (10)
176 (42)
204 (48)
BMI at age 40 s
kg/m
2(mean6SD)
22.463.2 24.162.9* 22.062.8
Cigarette smoking (%) 59 (22)* 35 (30)* 63 (15)
Alcohol consumption (%) 36 (13) 21 (18)* 42 (10)
DM (%) 49 (18)* 43 (36)* 52 (12)
Hypertension (%) 107 (39)* 78 (66)* 207 (49)
Hyperlipidemia (%) 49 (18)* 28 (24) 122 (29)
Cardiovascular disease (%) 63 (23) 38 (32) 119 (28)
APOE e4 carriers (%) 109 (40)* 25 (21) 61 (15)
*p,0.05 for comparing cases (AD and VaD) and controls.
Abbreviations: AD, Alzheimer’s disease; VaD, vascular dementia; BMI, body mass
index; DM, diabetes mellitus; APOE e4, apolipoprotein E e4.
doi:10.1371/journal.pone.0020573.t001
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association between NINJ2 genotypes and the risk of AD and VaD
by using the likelihood ratio test. We also tested the association
between NINJ2 polymorphisms and the risk of AD or VaD
stratified by APOE e4 status. SAS version 9.1 (SAS Institute, Cary,
NC) was used for statistical analyses and all statistical tests were
two-sided.
Results
This study included 275 incident AD cases, 119 small vessel
VaD cases, and 423 controls. As compared with controls (Table 1),
AD cases were older (78.2 vs. 71.4 years old), included more
females (65% vs. 57%), had a lower education level (#6 years:
51% vs. 10%), more smokers (22% vs. 15%), more DM (18% vs.
12%) and hypertension (39% vs. 49%) history, fewer with
hyperlipidemia (18% vs. 29%), and more APOE e4 carriers (40%
vs. 15%). The distributions of BMI, alcohol consumption, and
history of cardiovascular disease were similar between AD and
controls.
VaD cases were older (78.6 vs. 71.4), had a lower education
level (#6 years: 59% vs. 10%), a higher BMI (24.1 vs. 22 kg/
m
2), more smokers (30% vs. 15%), higher alcohol consumption
(18% vs. 10%), and more DM (36% vs. 12%) and hypertension
history (66% vs. 49%) as compared with controls (Table 1). The
distributions of gender, hyperlipidemia, cardiovascular disease,
and APOE e4 status were similar between VaD cases and
controls.
Five htSNPs of NINJ2 were genotyped. In this study, the minor
allele frequencies (MAFs) of the five SNPs ranged from 9% to
43%, which were similar to the MAFs of CHB genotype data in
HapMap database. All NINJ2 SNPs were in HWE among controls
(Table 2). For each SNP, the genotype frequencies were not
significantly different by disease status (data not shown).
Participants carrying two copies of variant SNP2 or SNP5 had
a significantly decreased risk of AD (SNP2: AOR =0.43, 95%
CI =0.23–0.80; SNP5: AOR =0.33, 95% CI =0.12–0.96,
Table 3) as compared with non-carriers. SNP2 remained
significantly associated with AD risk after controlling for FDR
(Table 3). In contrast, no NINJ2 SNP was associated with VaD
(Table 3). After stratified by APOE e4 genotype, SNP2 still
significantly associated with AD among non-APOE e4 carriers after
controlling for FDR (AOR =0.38, 95% CI =0.18–0.82, Table 4),
and only NINJ2 SNP4 was significantly associated with AD risk
Table 2. Characteristics of NINJ2 haplotype tagging SNPs.
SNP
name
Nucleotide
change Location rs no.
Minor allele
frequency (controls)
HWE p
(controls)
Minor allele
frequency (cases)
HWE p
(cases)
SNP1 CRA5 9UTR rs4980959 0.39 0.99 0.42 0.23
SNP2 GRA intron rs11833579 0.35 0.55 0.30 0.29
SNP3 ARG intron rs7298096 0.43 0.79 0.40 0.55
SNP4 GRA intron rs7314661 0.09 0.39 0.10 0.36
SNP5 GRA intron rs12425791 0.25 0.26 0.21 0.01
Abbreviations: SNP, single nucleotide polymorphism; HWE, Hardy-Weinberg equilibrium; UTR, untranslated region.
doi:10.1371/journal.pone.0020573.t002
Table 3. NINJ2 SNP analysis by genotype for dementia patients and controls.
Co-dominant model Additive model
SNP 0 copies 1 copy 2 copies
Case/control OR Case/control OR (95%CI) p Case/control OR (95%CI) p OR (95%CI)
AD (Global test P,0.0001)
SNP1 98/156 1.00 123/198 1.18 (0.81–1.72) 0.35 52/63 1.25 (0.76–2.07) 0.35 1.13 (0.89–1.43)
SNP2 127/172 1.00 121/196 0.97 (0.67–1.39) 0.81 21/49 0.43 (0.23–0.80) 0.01
* 0.76 (0.58–0.98)
SNP3 95/134 1.00 133/206 1.00 (0.69–1.47) 0.87 40/75 0.77 (0.46–1.29) 0.25 0.90 (0.70–1.15)
SNP4 224/346 1.00 46/72 1.09 (0.70–1.71) 0.69 4/2 2.99 (0.48–18.15) 0.23 1.20 (0.80–1.80)
SNP5 162/235 1.00 104/164 1.01 (0.71–1.44) 0.98 5/21 0.33 (0.12–0.96) 0.04 0.84 (0.63–1.14)
VaD (Global test P=0.43)
SNP1 47/156 1.00 55/198 1.13 (0.69–1.84) 0.55 15/63 0.83 (0.40–1.69) 0.65 0.97 (0.70–1.34)
SNP2 50/172 1.00 50/196 0.95 (0.58–1.54) 0.96 19/49 0.98 (0.49–1.96) 0.95 0.93 (0.67–1.29)
SNP3 39/134 1.00 59/206 1.05 (0.63–1.73) 0.91 17/75 0.92 (0.46–1.83) 0.64 0.98 (0.71–1.37)
SNP4 89/346 1.00 29/72 1.44 (0.83–2.47) 0.19 0/2 NA NA 1.27 (0.76–2.15)
SNP5 66/235 1.00 47/164 1.04 (0.65–1.66) 0.83 6/21 1.19 (0.43–3.30) 0.72 1.06 (0.72–1.54)
All models were adjusted for age and gender.
Abbreviation: NA, not applicable.
*Result remains significant after controlling for multiple tests by using FDR.
doi:10.1371/journal.pone.0020573.t003
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CI =1.07–8.61, Table 4).
Five htSNPs selected from seventeen common (frequency $5%)
SNPs spanning NINJ2 formed one block, which was determined
by modified Gabriel et al. algorithm [22,23] (Figure 1). The blocks
identified by the default settings in Haploview program were
merged if they had the multiallelic D’ greater than 0.8 and the
cumulative frequency of common (frequency .5%) haplotypes in
the merged block was greater than 80%. The five common
haplotypes were found with a cumulated frequency of 97.5% in
controls (Table 5). The p value for global test of the five common
haplotypes was 0.03 for AD and 0.70 for VaD. Participants
carrying two copies of the minor HAP2 CAGGA had a decreased
risk of AD (AOR =0.32, 95% CI =0.11–0.94). None of NINJ2
haplotypes was associated with AD and VaD risk under the
additive model. Result did not reach statistical significance for
VaD.
Among the vascular risk factors explored in this study (e.g.,
hypertension, DM, hyperlipidemia, smoking, and high BMI),
hyperlipidemia is the only one significantly modify the
association between NINJ2 polymorphisms and the risk of AD.
Hyperlipidemia status significantly lower the risk of AD (AOR
=0.43, 95% CI =0.27–0.71) as compared with participants
without this condition. Hyperlipidemia significantly modified the
association between HAP2 CAGGA and AD risk under the
recessive model (pinteraction =0.02, Table 6). After stratification by
hyperlipidemia status, participants without hyperlipidemia and
carrying two copies of minor HAP2 had a decreased risk of
AD as compared to those carrying 0 or 1 copy of HAP2 (AOR
=0.08, 95% CI =0.01–0.71, Table 6). In contrast, increased
AD risk was observed in participants with hyperlipidemia
and carrying 2 copies of minor HAP2 (AOR =1.40, 95%
CI =0.28–7.02). Other vascular risk factors did not modify the
relationship between NINJ2 haplotypes and AD risk (data not
shown). No significant interactions were observed for VaD risk
(data not shown).
Discussion
This study found that NINJ2 rs11833579 (SNP2), rs12425791
(SNP5) and HAP2 (CAGGA) were significantly associated with a
decreased risk of AD, which has not been reported previously.
Table 4. NINJ2 SNP analysis by APOE e4 status for Alzheimer’s disease patients and controls.
Co-dominant model Additive model
SNP 0 copies 1 copy 2 copies
Case/Control OR Case/ Control OR (95%CI) p Case/ Control OR (95%CI) p OR (95%CI)
Non-APOE e4 carriers
SNP1 55/134 1.00 80/172 1.32 (0.83–2.08) 0.22 28/48 1.39 (0.75–2.57) 0.29 1.21 (0.90–1.62)
SNP2 76/148 1.00 72/162 0.97 (0.62–1.50) 0.84 12/42 0.38 (0.18–0.82) 0.01
* 0.73 (0.54–1.00)
SNP3 58/106 1.00 79/181 0.86 (0.55–1.36) 0.42 22/63 0.70 (0.37–1.32) 0.22 0.84 (0.62–1.14)
SNP4 135/288 1.00 27/65 0.95 (0.56–1.64) 0.89 2/2 1.92 (0.25–14.81) 0.53 1.03 (0.63–1.67)
SNP5 102/199 1.00 57/137 0.86 (0.56–1.33) 0.51 4/19 0.38 (0.12–1.24) 0.11 0.77 (0.53–1.10)
APOE e4 carriers
SNP1 42/22 1.00 42/23 1.30 (0.58–2.93) 0.45 23/14 0.80 (0.30–2.11) 0.72 0.94 (0.57–1.53)
SNP2 51/22 1.00 48/32 0.78 (0.37–1.67) 0.48 9/7 0.47 (0.14–1.67) 0.24 0.72 (0.41–1.26)
SNP3 37/25 1.00 53/24 1.91 (0.83–4.37) 0.20 18/12 0.74 (0.27–2.03) 0.47 0.97 (0.58–1.60)
SNP4 88/55 1.00 19/6 2.73 (0.90–8.25) 0.08 2/0 NA NA 3.03 (1.07–8.61)
SNP5 59/33 1.00 47/26 1.17 (0.56–2.45) 0.84 1/2 0.38 (0.03–4.56) 0.40 1.00 (0.51–1.95)
All models were adjusted for age and gender.
Abbreviation: NA, not applicable.
*Result remains significant after controlling for multiple tests by using FDR.
doi:10.1371/journal.pone.0020573.t004
Figure 1. NINJ2 linkage disequilibrium plot. This plot was
generated by Haploview program using the modified Gabriel et al.
algorithm using data from this study. Five common haplotype
(frequency $0.05) were identified and formed one block. The SNP
name, e.g., SNP1, SNP2, etc., indicated five htSNP genotyped in this
study. The level of pair-wise D’, which indicated the degree of linkage
disequilibrium between two SNPs, was shown in the linkage
disequilibrium structure in red.
doi:10.1371/journal.pone.0020573.g001
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GWAS [9]. This indicated that dementia and ischemic stroke may
share common risk factors, e.g., vascular risk factors [26,27] and
cerebrovascular disease [28,29]. Neurofibrillar tangle (NFT) and
beta amyloid are important markers in the brain of AD patients
and they are also markers for the neurotoxic cascades and
degeneration process. NINJ2 plays a role in neurite growth,
ischemic tolerance, and inflammation response, its sequence
variations may reduce or block the signaling of the immune
response and thus lead to the formation of NFT and beta amyloid
and subsequently lower the risk of AD (Figure 2). NINJ2 also
affects dementia risk via nerve regeneration. A research found
that the expression level of NINJ2 was associated with axonal
regeneration [30], which may explain how the brain tolerates
ischemic insults.
Participants carrying two copy of minor HAP2 had a 0.32-fold
decreased risk of AD (Table 5). SNP2, SNP3 and SNP5 were SNPs
carrying variant alleles in HAP2. Because each variant allele was
associated with decreased AD risk (although SNP3 did not reach
statistical significance), HAP2 may result in a protective effect on
AD. However, no SNP or haplotype was related to small-vessel
VaD in this study, probably due to small sample size (119 VaD
cases) and moderate genetic effect. Our findings suggested that
NINJ2 polymorphisms played an important role in dementia risk,
which has not been explored so far.
It is well established that APOE plays a role in the metabolism
of cholesterol, which regulates the formation of neurofibrillar
tangle and Ab and the subsequent AD risk. After stratification by
APOE e4 status, variant SNP2 became a stronger protector for AD
among non-APOE e4 carriers (AOR =0.38, 95% CI =0.18–0.82)
as compared to APOE e4 carriers (AOR =0.47, 95% CI =0.14–
1.67). This may be attributable to the joint effect of lack of APOE
e4 allele and NINJ2 SNP2.
Vascular risk factors (e.g., hypertension, DM, smoking, and
higher BMI), have been associated with VaD risk in previous
studies [27,31]. We found that history of hyperlipidemia and
hypertension were protective factors for AD (data not shown),
which was consistent with a recent cohort study [32]. First, this
may be a result of using of medication for cardiovascular disease,
e.g., statin [33] and angiotensin converting enzyme inhibitors [34].
It is also possible that the participants recruited in this study were
survivors of people with high-risk of vascular diseases. Therefore,
they may carry genes related to lower risk of hyperlipidemia or
hypertension. In addition, we found that hyperlipidemia signifi-
Figure 2. Postulated pathway of NINJ2 and mediators involved in the formation of dementia. Solid lines indicated pathways have been
well documented; dotted lines indicated speculated pathway. NFT denotes neurofibrillar tangle. Ab denotes beta amyloid.
doi:10.1371/journal.pone.0020573.g002
Table 6. Interaction between HAP2 and hyperlipidemia on AD risk.
Hyperlipidemia HAP2 (CAGGA) pinteraction*
0 or 1 copy 2 copies
Case/Control OR Case/Control OR (95%CI)
No 221/285 1.00 1/15 0.08 (0.01–0.71) 0.02
Yes 45/117 1.00 4/5 1.40 (0.28–7.02)
All models were adjusted for age, gender, and APOE e4.
*p value was obtained by using the recessive model.
doi:10.1371/journal.pone.0020573.t006
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20573cantly modified the association between HAP2 and AD risk. It is
possible that hyperlipidemia was associated with the change of
acetylcholine, a neurotransmitter in central nervous system, which
increases brain perfusion and plays the vascular role in the
cholinergic neural system [35]. That is, ischemic insult resulting
from vascular risk factor, e.g., hyperlipidemia, may lead to
dementia occurrence [36]. However, the underlying mechanism
remains to be elucidated.
This study has several strengths. First, the association between
NINJ2 polymorphisms and dementia risk has not been explored
previously. Second, the selection of a set of representative htSNPs
captured the majority of genetic information of NINJ2 (r
2=0.79).
Third, as compared to SNPs, haplotypes provided a stronger
statistical power to detect the association between NINJ2 sequence
variants and dementia because these htSNPs are in highly linkage
disequilibrium. In addition, all dementia cases were confirmed by
brain imaging to minimize possible misclassification of dementia
subtypes. Last, because the clinical presentation of large-vessel
ischemia insults varied tremendously, inclusion of patients with
small-vessel dementia (e.g., lacunar infarction and leukoaraiosis)
provided homogeneous outcome.
This study had some limitations as well. First, the information of
vascular risk factors (e.g., hypertension, DM, and hyperlipidemia)
was obtained from a self-report questionnaire instead of medical
charts. However, these diseases are major health issues, and
participants’ awareness of these diseases/conditions was inquired
in the questionnaire if their disease/condition was diagnosed by
physicians. Therefore, information bias should not be a concern.
Second, medications for treating cardiovascular or cerebrovascular
diseases may affect the AD course [37]. This information may not
be available because our participants were recruited from
neurology clinics and they tended to look for other physicians
for diagnosis and treatment of vascular diseases. Last, this study
included 122 VaD cases and may not have sufficient statistical
power to assess the associations between NINJ2 polymorphisms
and VaD risk.
NINJ2 SNPs and a haplotype were significantly associated with
AD risk, which has not been explored previously, possibly through
inflammation and metabolic pathways. Also, we found that
hyperlipidemia significantly modify this association. Future large
studies are warranted to explore these associations.
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